AbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In Schizophrenia

AbbVie, Inc. (NYSE: ABBV ) announced the acquisition of Cerevel Therapeutics in December 2023. The deal strengthened AbbVie’s neuroscience pipeline, which now includes promising product candidates such as Emraclidine and Tavapadon. The transaction, with a cost of $8.7 billion, was completed lastOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedic ...